Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: A comparative cost analysis

Clinical Drug Investigation

Volumn 33, Issue 11, 2013, Pages 825-835

  Sicras, Antoni ^a   Rejas, Javier ^b   Navarro, Ruth ^c   Planas, Albert ^d  

^a Badalona Serveis Assistencials SA Gaietà Soler   (Spain)

^b PFIZER INC   (United States)

^c HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^d Hospital Municipal de Badalona   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; GABAPENTIN; OPIATE; PREGABALIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; SPAIN;

ADULT; AGED; AMINES; CYCLOHEXANECARBOXYLIC ACIDS; DIABETIC NEPHROPATHIES; DRUG COSTS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LONGITUDINAL STUDIES; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84886399566     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-013-0131-8     Document Type: Article

References (48)

1. Chen L, Magliano DJ, Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus-present and future perspectives. Nat Rev Endocrinol. 2011;8:228-36. doi: 10.1038/nrendo.2011.183.
2. Tousoulis D, Kampoli AM, Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol. 2012;10:19-32.
3. Vincent AM, Callaghan BC, Smith AL, et al. Diabetic neuropathy: cellular mechanisms as therapeutic targets. Nat Rev Neurol. 2011;7:573-83.
4. Selvarajah D, Wilkinson ID, Davies J, et al. Central nervous system involvement in diabetic neuropathy. Curr Diab Rep. 2011;11:310-22.
5. Obrosova IG. Diabetic painful and insensate neuropathy: pathogenesis and potential treatments. Neurotherapeutics. 2009;6:638-47.
6. Boulton AJM. Guidelines for the diagnosis and outpatient management of diabetic peripheral neuropathy. Diabet Med. 1998;15:508-14.
7. Veves A, Backonja M, Malik RA. Painful diabetic neuropathy: epidemiology, natural history, early diagnosis, and treatment options. Pain Med. 2008;9:660-74.
8. Hsu WC, Yen AM, Liou HH, et al. Prevalence and risk factors of somatic and autonomic neuropathy in prediabetic and diabetic patients. Neuroepidemiology. 2009;33:344-9.
9. Tesfaye S, Selvarajah D. Advances in the epidemiology, pathogenesis and management of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2012;1:8-14.
10. Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45-56.
11. Dworkin RH, Malone DC, Panarites CJ, et al. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain. 2010;11:360-8.
12. Boulanger L, Zhao Y, Bao Y, et al. A retrospective study on the impact of comorbid depression or anxiety on healthcare resource use and costs among diabetic neuropathy patients. BMC Health Serv Res. 2009;9:111.
13. Zhao Y, Ye W, Boye KS, et al. Prevalence of other diabetes-associated complications and comorbidities and its impact on health care charges among patients with diabetic neuropathy. J Diabetes Complications. 2010;24:9-19.
14. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab. 2009;35:206-13.
15. Bril V, England J, Franklin GM, et al.; American Academy of Neurology; American Association of Neuromuscular and Electrodiagnostic Medicine; American Academy of Physical Medicine and Rehabilitation. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65.
16. Samper Bernal D, Monerris Tabasco MM, Homs Riera M, et al. Etiología y manejo de la neuropatía diabética dolorosa. Rev Soc Esp Dolor. 2010;17:286-96.
17. Mitka M. Group releases new guideline on options for treating painful diabetic neuropathy. JAMA. 2011;305:2507-8.
18. Hovaguimian A, Gibbons CH. Clinical approach to the treatment of painful diabetic neuropathy. Ther Adv Endocrinol Metab. 2011;2:27-38.
19. Lesser H, Sharma U, Lamoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63:2104-10.
20. Rosenstock J, Tuchman M, Lamoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110:628-38.
21. Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain. 2005;6:253-60.
22. Freynhagen R, Grond S, Schüpfer G, et al. Efficacy and safety of pregabalin in treatment refractory patients with various neuropathic pain entities in clinical routine. Ínt J Clin Pract. 2007;61:1989-96.
23. Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol. 2008;8:33.
24. Hurley RW, Lesley MR, Adams MC, et al. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med. 2008;33:389-94.
25. Freeman R, Durso-Decruz E, Emir B. Efficacy, safety, and tolerability of pregabalin treatment for painful diabetic peripheral neuropathy: findings from seven randomized, controlled trials across a range of doses. Diabetes Care. 2008;31:1448-54.
26. Tölle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain. 2008;12:203-13.
27. Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med. 2011;28:109-16.
28. Gálvez R, Marsal C, Vidal J, et al. Cross-sectional evaluation of patient functioning and health-related quality of life in patients with neuropathic pain under standard care conditions. Eur J Pain. 2007;11:244-55.
29. Navarro A, Saldaña MT, Pérez C, et al. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med. 2010;11:719-31.
30. Saldaña MT, Navarro A, Pérez C, et al. Patient-reported- outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int. 2010;30:1005-15.
31. Pérez C, Navarro A, Saldaña MT, et al. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: findings from a cost-consequences analysis in a nested case-control study. Clin Ther. 2010;32:1357-70.
32. Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R, et al. Cost analysis of adding pregabalin or gabapentin to the management of community-treated patients with peripheral neuropathic pain. J Eval Clin Pract. 2011;18:1170-9. doi: 10.1111/j.1365-2753.2011.01752.x.
33. Udall M, Harnett J, Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J Med Econ. 2012;15:361-70.
34. Gore M, Tai KS, Zlateva G, et al. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract. 2011;11:528-39.
35. Lamberts H, Wood M, Hofmans-Okkes ÍM, editors. The international classification of primary care in the European community: with a multi-language layer. Oxford: Oxford University Press; 1993.
36. WHO Collaborating Centre for Drug Statistic Methodology. Norwegian Institute of Public Health. The Anatomical Therapeutic Chemical (ATC) classification system, Oslo; 1991. http://www.whocc.no. Accessed 29 May 2012.
37. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-83.
38. Weiner JP, Starfield BH, Steinwachs DM, et al. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care. 1991;29:452-72.
39. Gore M, Sadosky A, Tai KS, et al. A retrospective evaluation of the use of gabapentin and pregabalin in patients with post-herpetic neuralgia in usual-care settings. Clin Ther. 2007;29:1655-70.
40. Consejo General de Colegios Oficiales de Farmacéuticos. Catálogo de Especialidades Farmacéuticas. Madrid: Consejo General de Colegios Oficiales de Farmacéuticos; 2010.
41. National Institute of Statistics. Encuesta de costes laborales del año 2010, Spain; 2010. http://www.ine.es/infoine. Accessed Feb 2012.
42. Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? BMJ. 2000;320:1197-200.
43. Navarro A, Saldana MT, Perez C, et al. A cost-consequences analysis of the effect of pregabalin in the treatment of peripheral neuropathic pain in routine medical practice in primary care settings. BMC Neurol. 2011;11:7.
44. Baron R, Freynhagen R, Tölle TR, et al.; A0081007 Investigators. The efficacy and safety of pregabalin in the treatment of neuropathic pain associated with chronic lumbosacral radiculopathy. Pain 2010;150:420-7.
45. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther. 2003;25:81-104.
46. Van Seventer R, Sadosky A, Lucero M, et al. A cross-sectional survey of health state impairment and treatment patterns in patients with post-herpetic neuralgia. Age Ageing. 2006;35:132-7.
47. Quilici S, Chancellor J, Löthgren M, et al. Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain. BMC Neurol. 2009;9:6.
48. Vetter TR. The application of economic evaluation methods in the chronic pain medicine literature. Anesth Analg. 2007;105:114-8.